Wave Life Sciences Ltd. WVE 深 滬
已收盤 02-06 16:00:00 美东时间
13.45
+0.700
+5.49%
華盛通- 最 高13.505
- 今 開13.13
- 成交量 273.02万股
- 最 低 12.995
- 昨 收 12.75
- 總市值 24.98亿
- 52周最高 21.73
- 市盈率 靜 --
- 換手率 1.47%
- 52周最低 5.28
- 委 比 19.40%
- 總股本 1.86亿
- 歷史最高 56.00
- 量 比 1.00
- 振 幅 4.00%
- 歷史最低 1.16
- 每 手 1
- 風險率 3.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 谷歌绩后获14家大行上调目标价；Arm、高通、波士顿科学、艾可菲、Snap、优步遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Wave Life Sciences Ltd."超配"评级，目标价从34美元升至41美元；Piper Sandler：维持Replimune Group"超配"评级，目标价从13美元升至14美元
02-06 16:52
美股机会日报 | 美国1月“小非农”不及预期！礼来绩后一度大涨10%，财报强劲超预期
“小非农”不及预期！美国1月仅新增2.2万个就业岗位；美联储“新主席”生变？民主党人阻挠沃什获提名；礼来绩后一度大涨10%，财报强劲超预期；黄金强势反弹至5000美元上方>>
02-04 22:18
美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
BUZZ-U.S. STOCKS ON THE MOVE-Abacus Global, McDonald's, Wave Life
BUZZ-U.S. STOCKS ON THE MOVE-Abacus Global, McDonald's, Wave Life Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes climbed on Monday as a rally in memory ch
02-03 02:45
Wave Life Sciences Regained Full Rights to WVE-006 From GSK
This follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to efficiently advance the WVE-006 program in AATD, a rare condition. This agreement was made
02-02 20:33
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences has regained full rights to WVE-006, a first-in-class RNA editing therapy for alpha-1 antitrypsin deficiency (AATD), from GSK. WVE-006 aims to address both lung and liver manifestations of AATD, with no current therapies targeting both. Wave plans to engage with the FDA on a potential accelerated approval pathway, with regulatory feedback expected mid-2026. Clinical data from the 400 mg and 600 mg cohorts of the RestorAATion-2 ...
02-02 12:30
Wave Life Sciences sets 2026 strategy, highlights obesity program
Wave Life Sciences ( ($WVE) ) has issued an update. On January 12, 2026, Wave L...
01-12 20:59
Oppenheimer’s best small and mid-cap ideas for 2026
Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year. Analysts said that, absent the traditional warning signs that have historically preceded market down...
01-07 00:59
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
<p>Wave Life Sciences Ltd. (Nasdaq: WVE), a biotechnology company specializing in RNA medicines, announced that its CEO, Paul Bolno, MD, MBA, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, at 2:15 p.m. PT / 5:15 p.m. ET. A live webcast and replay of the presentation will be available on the company's website. Wave focuses on developing RNA-based therapies for treating rare and common diseas...
01-05 13:30
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
